id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-329779-5sauq4gp	Sanchis-Gomar, Fabian	In Reply – Association of Renin Angiotensin System Blockers with Outcomes in Patients With COVID-19	2020-09-14		.txt	text/plain	732	46	50	To the Editor: Current guidelines and health professional recommendations endorse the continuation of both anti-hypertensives angiotensin-converting enzyme (ACE) inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs) for managing hypertension (HTN) during the COVID-19 pandemic. 1, 2 In the meta-analysis of Garg et al., 3 which included studies published until May 31, 2020, both mortality or severe disease risk were not increased among J o u r n a l P r e -p r o o f patients using ACEIs/ARBs. However, it was noted that administration of these drugs might reduce mortality in patients with HTN. 4 in which no beneficial association of ACEI/ARB use was found for COVID-19 severity or mortality, as would be expected given the normal circulating J o u r n a l P r e -p r o o f levels of AngII. Only retrospective observational studies regarding the potentially deleterious effects of ACEIs/ARBs in COVID-19 patients have been conducted to-date, and these findings need to be confirmed in prospective randomized controlled trials (RCT).	./cache/cord-329779-5sauq4gp.txt	./txt/cord-329779-5sauq4gp.txt